Literature DB >> 19745559

The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

Jan Terje Andersen1, Inger Sandlie.   

Abstract

SUMMARY: The half-life of the two most abundant proteins in blood, immunoglobulin G (IgG) and serum albumin, is extraordinary (approximately 19-23 days) compared to other circulating proteins. This phenomenon secures a broad biodistribution throughout the body of both molecules. The long half-life has made IgG the natural choice for engineering of antibody based therapeutics, while albumin is used as a fusion partner for or carrier of drugs. Remarkably, the half-life of these unrelated proteins has been shown prolonged by a receptor recycling pathway mediated by a common cell bound receptor named the neonatal Fc receptor (FcRn). This review summarizes our current understanding of FcRn function and discusses its relevance for development of new IgG and albumin based therapeutics and diagnostics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19745559     DOI: 10.2133/dmpk.24.318

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  39 in total

1.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Authors:  Adam R Mezo; Vandana Sridhar; John Badger; Paul Sakorafas; Vicki Nienaber
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

3.  Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Authors:  M W Nolte; T C Nichols; J Mueller-Cohrs; E P Merricks; I Pragst; S Zollner; G Dickneite
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

4.  Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.

Authors:  Jan Terje Andersen; Bjørn Dalhus; Dorthe Viuff; Birgitte Thue Ravn; Kristin Støen Gunnarsen; Andrew Plumridge; Karen Bunting; Filipa Antunes; Rebecca Williamson; Steven Athwal; Elizabeth Allan; Leslie Evans; Magnar Bjørås; Søren Kjærulff; Darrell Sleep; Inger Sandlie; Jason Cameron
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

5.  Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.

Authors:  Kine Marita Knudsen Sand; Bjørn Dalhus; Gregory J Christianson; Malin Bern; Stian Foss; Jason Cameron; Darrell Sleep; Magnar Bjørås; Derry C Roopenian; Inger Sandlie; Jan Terje Andersen
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

6.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

7.  Structural insights into neonatal Fc receptor-based recycling mechanisms.

Authors:  Vaheh Oganesyan; Melissa M Damschroder; Kimberly E Cook; Qing Li; Changshou Gao; Herren Wu; William F Dall'Acqua
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

8.  Albumin and mammalian cell culture: implications for biotechnology applications.

Authors:  Geoffrey L Francis
Journal:  Cytotechnology       Date:  2010-04-06       Impact factor: 2.058

Review 9.  Neonatal Fc receptor: from immunity to therapeutics.

Authors:  Timothy T Kuo; Kristi Baker; Masaru Yoshida; Shuo-Wang Qiao; Victoria G Aveson; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

10.  Human podocytes perform polarized, caveolae-dependent albumin endocytosis.

Authors:  Evgenia Dobrinskikh; Kayo Okamura; Jeffrey B Kopp; R Brian Doctor; Judith Blaine
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.